Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.92
FLML's Cash to Debt is ranked lower than
81% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. FLML: 0.92 )
Ranked among companies with meaningful Cash to Debt only.
FLML' s 10-Year Cash to Debt Range
Min: 0.08  Med: 11.99 Max: N/A
Current: 0.92
Equity to Asset 0.12
FLML's Equity to Asset is ranked lower than
90% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. FLML: 0.12 )
Ranked among companies with meaningful Equity to Asset only.
FLML' s 10-Year Equity to Asset Range
Min: -0.32  Med: 0.53 Max: 0.8
Current: 0.12
-0.32
0.8
F-Score: 4
Z-Score: 0.85
M-Score: 2.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -155.61
FLML's Operating margin (%) is ranked lower than
58% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. FLML: -155.61 )
Ranked among companies with meaningful Operating margin (%) only.
FLML' s 10-Year Operating margin (%) Range
Min: -1285  Med: -63.41 Max: 15.94
Current: -155.61
-1285
15.94
Net-margin (%) -121.64
FLML's Net-margin (%) is ranked lower than
57% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. FLML: -121.64 )
Ranked among companies with meaningful Net-margin (%) only.
FLML' s 10-Year Net-margin (%) Range
Min: -1027.16  Med: -60.63 Max: 22.56
Current: -121.64
-1027.16
22.56
ROE (%) -104.45
FLML's ROE (%) is ranked lower than
81% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. FLML: -104.45 )
Ranked among companies with meaningful ROE (%) only.
FLML' s 10-Year ROE (%) Range
Min: -1103.89  Med: -29.09 Max: 30.36
Current: -104.45
-1103.89
30.36
ROA (%) -26.45
FLML's ROA (%) is ranked higher than
51% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. FLML: -26.45 )
Ranked among companies with meaningful ROA (%) only.
FLML' s 10-Year ROA (%) Range
Min: -58.46  Med: -17.61 Max: 14.58
Current: -26.45
-58.46
14.58
ROC (Joel Greenblatt) (%) -250.61
FLML's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. FLML: -250.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FLML' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1730.55  Med: -92.24 Max: 80.38
Current: -250.61
-1730.55
80.38
Revenue Growth (3Y)(%) -32.30
FLML's Revenue Growth (3Y)(%) is ranked lower than
75% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. FLML: -32.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
FLML' s 10-Year Revenue Growth (3Y)(%) Range
Min: -52.8  Med: -1.20 Max: 42.6
Current: -32.3
-52.8
42.6
EBITDA Growth (3Y)(%) 106.50
FLML's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. FLML: 106.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
FLML' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -50.2  Med: -15.00 Max: 126.3
Current: 106.5
-50.2
126.3
EPS Growth (3Y)(%) 89.50
FLML's EPS Growth (3Y)(%) is ranked higher than
97% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. FLML: 89.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
FLML' s 10-Year EPS Growth (3Y)(%) Range
Min: -38.2  Med: -17.20 Max: 89.5
Current: 89.5
-38.2
89.5
» FLML's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

FLML Guru Trades in

FLML Guru Trades in

Q1 2015

FLML Guru Trades in Q1 2015

Steven Cohen 355,800 sh (New)
» More
Q2 2015

FLML Guru Trades in Q2 2015

Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FLML

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 19.16
FLML's Forward P/E is ranked higher than
63% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. FLML: 19.16 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 40.34
FLML's P/B is ranked lower than
98% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. FLML: 40.34 )
Ranked among companies with meaningful P/B only.
FLML' s 10-Year P/B Range
Min: 1.83  Med: 4.64 Max: 44.04
Current: 40.34
1.83
44.04
P/S 24.39
FLML's P/S is ranked lower than
69% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. FLML: 24.39 )
Ranked among companies with meaningful P/S only.
FLML' s 10-Year P/S Range
Min: 2.3  Med: 6.28 Max: 184.88
Current: 24.39
2.3
184.88
PFCF 67.24
FLML's PFCF is ranked lower than
66% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 40.25 vs. FLML: 67.24 )
Ranked among companies with meaningful PFCF only.
FLML' s 10-Year PFCF Range
Min: 15.77  Med: 52.30 Max: 702
Current: 67.24
15.77
702
POCF 58.39
FLML's POCF is ranked lower than
73% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.50 vs. FLML: 58.39 )
Ranked among companies with meaningful POCF only.
FLML' s 10-Year POCF Range
Min: 12.06  Med: 25.25 Max: 63.74
Current: 58.39
12.06
63.74
Current Ratio 1.67
FLML's Current Ratio is ranked lower than
79% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. FLML: 1.67 )
Ranked among companies with meaningful Current Ratio only.
FLML' s 10-Year Current Ratio Range
Min: 0.57  Med: 2.73 Max: 6.76
Current: 1.67
0.57
6.76
Quick Ratio 1.60
FLML's Quick Ratio is ranked lower than
75% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. FLML: 1.60 )
Ranked among companies with meaningful Quick Ratio only.
FLML' s 10-Year Quick Ratio Range
Min: 0.52  Med: 2.62 Max: 6.7
Current: 1.6
0.52
6.7
Days Inventory 423.99
FLML's Days Inventory is ranked lower than
93% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. FLML: 423.99 )
Ranked among companies with meaningful Days Inventory only.
FLML' s 10-Year Days Inventory Range
Min: 17.66  Med: 80.13 Max: 1276.2
Current: 423.99
17.66
1276.2
Days Sales Outstanding 51.22
FLML's Days Sales Outstanding is ranked higher than
61% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. FLML: 51.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
FLML' s 10-Year Days Sales Outstanding Range
Min: 39.95  Med: 75.18 Max: 541.87
Current: 51.22
39.95
541.87

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 3.86
FLML's Price/Median PS Value is ranked lower than
90% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. FLML: 3.86 )
Ranked among companies with meaningful Price/Median PS Value only.
FLML' s 10-Year Price/Median PS Value Range
Min: 0.24  Med: 0.96 Max: 28.62
Current: 3.86
0.24
28.62
Earnings Yield (Greenblatt) (%) -3.87
FLML's Earnings Yield (Greenblatt) (%) is ranked higher than
59% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. FLML: -3.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FLML' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.8  Med: 1.85 Max: 3.7
Current: -3.87
0.8
3.7

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 190 206 297
EPS($) 1.02 1.15 2.15
EPS without NRI($) 1.02 1.15 2.15

Business Description

Industry: Biotechnology » Biotechnology
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:FL3.Germany,
Flamel Technologies was incorporated as a Societe Anonyme or SA, a form of corporation under the laws of the Republic of France in August 1990 as Flamel Technologies S.A. The Company is a specialty pharmaceutical company with a history in drug delivery, working on the development of safer and more efficacious formulations. The acquisition of Éclat on March 13, 2012 has created a more vertically integrated company, benefiting from greater development and commercial expertise and more near-term and mid-term potential value creating catalysts. Since its acquisition of Eclat, Flamel is now engaged in not only on the development and licensing of versatile, proprietary drug delivery platforms but also on the development of novel, high-value products based on those delivery platforms. Bloxiverz, the Company first NDA approval from the portfolio of Eclat products acquired in March 2012. Bloxiverz's NDA was filed in August 2012 and approved by the FDA on May 2013. The launch of Bloxiverz commenced in July 2013. Bloxiverz is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Bloxiverz is the first and only FDA-approved version of neostigmine methylsulfate, even though other versions of neostigmine have been on the market as unapproved, grandfathered products under the Food, Drug and Cosmetic Act of 1938. Coreg CR, the lead product using its Micropump drug delivery platform. Coreg CR is an extended-release formulation once-a-day of Coreg a non-selective antagonist of Beta 1, Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors. The Company faces competition from Actavis, Alkermes, BioAlliance Pharma, Depomed, Ethypharm, Octoplus, Veloxis Pharmaceuticals, Nektar Therapeutics. The Company owns and develops drug delivery platforms that are able to tackle key challenges in the formulation, in various dosage forms of a broad range of drugs novel, already-marketed, or off-patent that includes Micropump. During the 2013 the Company has 395 patents in total. The design, testing, manufacturing and marketing of certain new or substantially modified drugs, biological products or medical devices must be approved, cleared or certified by regulatory agencies, regulatory authorities and Notified Bodies under applicable laws and regulations, the requirements of which may vary from country to country.
» More Articles for FLML

Headlines

Articles On GuruFocus.com
Flamel Technologies Announces Results of 2015 Annual Meeting; Domestic U.S. Public Company Reporting Jul 22 2015 
Flamel Technologies to Report Second Quarter of Fiscal Year 2015 Results Jul 20 2015 
Flamel Technologies Announces Positive Results From First Clinical Trials With Trigger Lock(TM) Hydr Jun 29 2015 
Flamel Technologies Appoints SVP of Quality and Regulatory Affairs and VP of Business and Corporate Jun 26 2015 
Flamel Technologies Announces Price Change for Bloxiverz Jan 15 2015 
Flamel Technologies Update to Shareholders on Neostigmine Methylsulfate Jan 14 2015 
Flamel Technologies Announces Positive Results of a Second Clinical Trial With Micropump(R) Sodium O Dec 19 2014 
Flamel Technologies Transfers Intangible Property to Irish-Based Subsidiary in Global Reorganization Dec 16 2014 
Flamel Technologies to Be Included in NASDAQ Biotech Index Dec 15 2014 
Flamel Technologies Sells Development and Manufacturing Facility in Pessac, France to Recipharm AB Nov 28 2014 

More From Other Websites
Top 10 Funds & Stocks at Risk of Being Squeezed in Market Turmoil Aug 25 2015
Edited Transcript of FLML earnings conference call or presentation 30-Jul-15 2:00pm GMT Jul 31 2015
Flamel Technologies Announces Second Quarter Results of Fiscal Year 2015 Jul 30 2015
Half Year 2015 Flamel Technologies SA Earnings Release - Before Market Open Jul 30 2015
Can The Uptrend Continue for Flamel (FLML)? - Tale of the Tape Jul 23 2015
Flamel Technologies Announces Results of 2015 Annual Meeting; Domestic U.S. Public Company Reporting... Jul 22 2015
Flamel Technologies to Report Second Quarter of Fiscal Year 2015 Results Jul 20 2015
SINA, AeroVironment, Golar LNG Among Wednesday's After-Hours Movers Jul 01 2015
Flamel Technologies Announces Positive Results From First Clinical Trials With Trigger Lock(TM)... Jun 29 2015
Flamel Technologies Appoints SVP of Quality and Regulatory Affairs and VP of Business and Corporate... Jun 26 2015
Broadfin Capital Thinks ContraFect Corp (CFRX) Can Prevent 25% of Deaths Jun 22 2015
Flamel Technologies to Present at JMP Securities Life Sciences Conference Jun 16 2015
PVH Corp, Atlantic Power, Carlyle Group Lead Monday's After-Hours Movers Jun 01 2015
Updated Time - Flamel Technologies to Present at Jefferies 2015 Healthcare Conference May 27 2015
Why Flamel Technologies (FLML) Could Be Positioned for a Surge? - Tale of the Tape May 26 2015
Flamel Technologies to Present at Jefferies 2015 Healthcare Conference May 22 2015
Heron Therapeutics (HRTX) Worth Watching: Stock Up 11.4% - Tale of the Tape May 18 2015
Onconova Therapeutics (ONTX) Looks Good: Stock Up 5.8% - Tale of the Tape May 18 2015
Auris Medical Holding AG (EARS) Looks Good: Stock Up 6.1% - Tale of the Tape May 15 2015
Flamel Technologies Announces First Quarter Results of Fiscal Year 2015 May 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK